Related Experiment Video

Updated: Aug 3, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia

C Wenisch1, H Laferl, M Szell

  • 1Abteilung für Infektionen und Tropenmedizin, Kaiser-Franz-Josef-Spital, Kundratstrasse 3, 1100 Vienna, Austria. christoph.wenisch@wienkav.at

Infection
|June 29, 2006
PubMed
Abstract

Insights

This study shows a multi-intervention approach effectively cures Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and eradicates the bacteria. The treatment regimen led to successful MRSA clearance in critically ill patients.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pharmacology

Background:

  • Increasing incidence of Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia in European intensive care units (ICUs).
  • Need for effective treatment and eradication strategies for nosocomial MRSA pneumonia.

Purpose of the Study:

  • To evaluate the efficacy of a comprehensive treatment protocol for MRSA pneumonia.
  • To assess the eradication rates of MRSA in critically ill patients.

Main Methods:

  • Observational study involving 21 critically ill patients with MRSA pneumonia.
  • Multi-intervention treatment: intravenous linezolid and rifampicin, endotracheal vancomycin, chlorhexidine, mupirocin, and povidone-iodine.
  • Collection of control samples to monitor MRSA eradication over time.

Main Results:

  • Clinical cure of pneumonia in all 20 surviving patients.
  • Complete MRSA eradication achieved in all patients post-treatment.
  • No MRSA reinfection observed during the follow-up period.

Conclusions:

  • A 7-day course of intravenous linezolid plus rifampicin, combined with local antiseptics, is effective for MRSA pneumonia treatment.
  • This multi-modal approach successfully eradicates MRSA, preventing reinfection.
  • The regimen offers a promising strategy for managing MRSA pneumonia in intensive care settings.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Automated Hospital Room Disinfection Utilizing a Novel Aerosolized Hydrogen Peroxide Microdroplet Disbursing Technology06:27

Automated Hospital Room Disinfection Utilizing a Novel Aerosolized Hydrogen Peroxide Microdroplet Disbursing Technology

Published on: February 24, 2026

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...